GlobeNewsWire
27 May 2026, 06:30 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/27/3301633/0/en/Aligos-Therapeutics-Presents-Positive-Data-at-the-EASL-Congress-2026.html
Read source
Search tags
Story key points
4 claims · impact-rated
Combination of pevifoscorvir sodium and antisense oligonucleotide ALG-170675 showed additive to synergistic effects on reducing HBV viral markers. — Synergistic results in a combination therapy increase the probability of achieving a 'functional cure,' which is the highest value milestone in HBV treatment.
+0.80Pevifoscorvir sodium monotherapy data suggests it can reduce the cccDNA reservoir, potentially making more patients eligible for functional cure therapies. — Reducing the cccDNA reservoir is a critical hurdle in HBV treatment; evidence of this mechanism elevates the drug's potential as a standard-of-care replacement.
+0.6040% of participants with baseline HBsAg ≥3,000 IU/mL achieved levels <3,000 IU/mL at 48 weeks using pevifoscorvir sodium. — Lowering HBsAg levels is a key prerequisite for other functional cure agents to work, expanding the addressable patient population for Aligos' pipeline.
+0.40Preclinical data for the hepatitis delta virus (HDV) program indicates a novel approach to targeting HDV replication. — While positive, preclinical data is early-stage and has significantly less immediate market impact than clinical human data.
+0.20Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company announced positive data from ten presentations at the EASL Congress 2026, highlighting the potential of its therapies for HBV.
